摘要
目的观察左卡尼汀注射液联合麝香保心丸治疗缺血性心肌病心衰的临床疗效，探索缺血性心肌病心衰的治疗方法。方法将65例患者按随机数字法随机分为联合治疗组和对照组，联合治疗组33例，对照组32例，对照组予以抗血小板类药物、他汀类药物、硝酸酯类药物、B受体阻滞剂、螺内酯、利尿剂口服；联合治疗组在对照组的基础上加用左卡尼汀注射液静滴、麝香保心丸口服，连续治疗7d后评价疗效。结果联合治疗组、对照组治疗前后，左室收缩末期内径（LVESD）、左室收缩末期容积（LVESV）、Nt—proBNP、TNF—α水平较治疗前有明显下降，治疗前后比较差异有统计学意义（P〈0．05）治疗后联合治疗组LVESD（5．10±1．30）cm、LVESV（127．00±39．00）ml、Nt—proBNP（315．60±17．60）pg／ml、TNF—α（1．74±2．10）pg／ml降低水平均优于对照组，同组治疗前后差异有统计学意义（P〈0．05）。结论左卡尼汀注射液联合麝香保心丸治疗缺血性心肌病心衰能更好地改善患者症状，提高患者生活质量，减少住院次数，是治疗缺血性心肌病心衰的有效方法之一。
Objective To observe the clinical efficacy of L-camifine injection combined with heart- protecting musk pill （HMP） in the treatment of ischemic cardiomyopathy heart failure, and explore treatment method of ischemic cardiomyopathy heart failure. Methods 65 patients were randomly divided into combined treatment group （33 cases） and control group （32 cases）. Control group was treated with antiplatelet drugs, statins, nitrates, β by blockers, spironolactone, diuretics orally; combined treatment group was treated with L-camitine intravenous injection, HMP orally on the basis of control group. Evaluated clinical efficacy after 7 days of treatment. Results Left ventricular systolic diameter （LVESD）, left ventricular end-systolic volume （LVESV）, Nt-proBNP, TNF-α
significantly decreased after treatment in both two groups （P〈0.05）. After treatment, LVESD [（5.10±1.30）cm], LVESV [（127.00±39.00）ml], Nt-proBNP [（315.60±17.60）pg/ml], TNF-α [（1.74±2.10）pg/ml] in combined treatment group were lower than those in control group, with statistically significant differences （P〈0.05）. Conclusion L-caruitine injection combined with HMP in the treatment of ischemic cardiomyopathy heart failure can better improve symptoms, improve quality of life, reduce the frequency of hospitalization, which is an effective method for the treatment of ischemic cardiomyopathy heart failure.
出处
《国际医药卫生导报》
2015年第24期3626-3628,共3页
International Medicine and Health Guidance News
